Adaptive Biotechnologies (ADPT) Revenue (2018 - 2026)

Adaptive Biotechnologies has reported Revenue for 9 years, with the latest figure at $70.9 million in Q1 2026.

• Quarterly Revenue rose 35.14% year-over-year to $70.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $295.4 million (up 55.87% YoY) and the FY2025 annual result came in at $277.0 million, up 54.77% from the prior year.
• Revenue declined to $70.9 million in Q1 2026 per ADPT's latest filing, from $71.7 million in the prior quarter.
• Over five years, Revenue peaked at $94.0 million in Q3 2025 and troughed at $7.7 million in Q2 2023.
• A 5-year average of $49.5 million and a median of $46.4 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue slumped 82.36% in 2023, then surged 460.91% in 2024.
• Over 5 years, Revenue stood at $55.2 million in 2022, then slipped by 17.05% to $45.8 million in 2023, then advanced by 3.66% to $47.5 million in 2024, then jumped by 51.04% to $71.7 million in 2025, then declined by 1.13% to $70.9 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $70.9 million, $71.7 million, and $94.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.